<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997035</url>
  </required_header>
  <id_info>
    <org_study_id>H9332-33965-02_2</org_study_id>
    <secondary_id>U10EY018573</secondary_id>
    <nct_id>NCT00997035</nct_id>
  </id_info>
  <brief_title>The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo</brief_title>
  <acronym>MUTTII</acronym>
  <official_title>The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Hospitals, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lumbini Eye Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bharatpur Eye Hospital, Nepal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the addition of oral voriconazole to topical
      treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fungal corneal ulcers tend to have very poor outcomes with commonly used treatments. There
      has only been a single randomized trial of anti-fungal therapy for mycotic keratitis, and no
      new ocular anti-fungal medications have been approved by the FDA since the 1960s. The
      triazole voriconazole has recently become the treatment of choice for systemic fungal
      infections such as pulmonary aspergillosis. The use of topical ophthalmic preparations of
      voriconazole has been described in numerous case reports, however there has been no
      systematic attempt to determine whether it is more or less clinically effective than
      natamycin. Additionally, there have been many case reports of the use of oral voriconazole in
      the treatment of fungal corneal ulcers, however there has been no systematic attempt to
      determine if it improves outcomes in severe ulcers.

      This study is a randomized, double-masked, placebo-controlled trial to determine if the use
      of oral voriconazole in severe ulcers reduces the rate of perforations. 240 fungal corneal
      ulcers with baseline visual acuity worse than 6/120 presenting to the Aravind Eye Hospitals
      and the UCSF Proctor Foundation will be randomized to receive oral voriconazole plus topical
      voriconazole and topical natamycin, or oral placebo plus topical voriconazole and topical
      natamycin. The primary outcome is the rate of perforation over the three month follow-up
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Perforation or Therapeutic Penetrating Keratoplasty</measure>
    <time_frame>3 months from enrollment</time_frame>
    <description>Hazard ratio of perforation or therapeutic penetrating keratoplasty (TPK) comparing voriconazole to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-corrected logMAR Visual Acuity</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Best spectacle-corrected logMAR visual acuity at 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-corrected logMAR Visual Acuity at 3-weeks</measure>
    <time_frame>3 weeks after enrollment</time_frame>
    <description>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Infiltrate/Scar - 3 Months</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Size of infiltrate/scar at 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Infiltrate/Scar</measure>
    <time_frame>3 weeks after enrollment</time_frame>
    <description>Size of infiltrate/scar at 3 weeks after enrollment, using enrollment infiltrate scar/size as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hazard Ratio for Re-epithelialization</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Hazard Ratio of re-epithelialization comparing the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cure at 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>Fungal Culture negative at 7 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3-months from enrollment</time_frame>
    <description>Comparing the number of serious and non-serious adverse events by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Inhibitory Concentration of Isolates</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Comparing Minimum inhibitory concentration of isolates by treatment arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Corneal Ulcer</condition>
  <condition>Eye Infections, Fungal</condition>
  <arm_group>
    <arm_group_label>Oral Voriconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
    <arm_group_label>Oral Voriconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a corneal ulcer at presentation

          -  Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)

          -  Visual acuity worse than 6/120 (20/400, logMAR 1.3)

          -  The patient must be able to verbalize a basic understanding of the study after it is
             explained to the patient, as determined by physician examiner. This understanding must
             include a commitment to return for follow-up visits.

          -  Willingness to be treated as an inpatient or to be treated as an outpatient and return
             every 3 days +/- 1 day until re-epithelialization and every week to receive fresh
             medication for 3 weeks

          -  Appropriate consent

        Exclusion Criteria:

          -  Evidence of bacteria on Gram stain at the time of enrollment

          -  Evidence of acanthamoeba by stain

          -  Evidence of herpetic keratitis by history or exam

          -  Corneal scar not easily distinguishable from current ulcer

          -  Age less than 16 years (before 16th birthday)

          -  Bilateral ulcers

          -  Previous penetrating keratoplasty in the affected eye

          -  Pregnancy (by history or urine test) or breast feeding (by history)

          -  Known liver disease, including hepatitis or cirrhosis (Child-Pugh A-C)

          -  Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected,
             corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)

          -  Acuity better than 6/120 (20/400) in the study eye (note that any acuity, uncorrected,
             corrected, pinhole, or BSCVA can be used for enrollment)

          -  Currently on rifampin, rifabutin, ritonavir, long acting barbiturates, phenytoin,
             carbamazepine, or other drugs known to interact with voriconazole

          -  Known allergy to study medications (antifungal or preservative)

          -  No light perception in the affected eye

          -  Not willing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NV Prajna, DNB, FRC Ophth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aravind Eye Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nisha Acharya, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proctor Foundation, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospitals</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Pondicherry</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Tirunelveli</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharatpur Eye Hospital</name>
      <address>
        <city>Bharatpur</city>
        <state>Chitwan</state>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumbini Eye Institute</name>
      <address>
        <city>Bhairahawa</city>
        <state>Lumbini</state>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Nepal</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>June 9, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>Fungal Infections</keyword>
  <keyword>Eye Disease</keyword>
  <keyword>Fungal Keratitis</keyword>
  <keyword>Visual Acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Eye Infections, Fungal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Oral Voriconazole</title>
          <description>Voriconazole: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>3-week Followup Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3-month Follow-up Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Oral Voriconazole</title>
          <description>Voriconazole: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="45" upper_limit="60"/>
                    <measurement group_id="B2" value="54" lower_limit="42" upper_limit="62"/>
                    <measurement group_id="B3" value="54" lower_limit="45" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nepal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (lbs)</title>
          <units>lbs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" lower_limit="97" upper_limit="121"/>
                    <measurement group_id="B2" value="105" lower_limit="94" upper_limit="123"/>
                    <measurement group_id="B3" value="108" lower_limit="97" upper_limit="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Perforation or Therapeutic Penetrating Keratoplasty</title>
        <description>Hazard ratio of perforation or therapeutic penetrating keratoplasty (TPK) comparing voriconazole to placebo</description>
        <time_frame>3 months from enrollment</time_frame>
        <population>Comparison of rate of perforation or TPK between the treatment groups (topical voriconazole with oral voriconazole vs. topical voriconazole with oral placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>oral voriconazole plus topical antifungal agents</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo plus topical antifungal agents</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Perforation or Therapeutic Penetrating Keratoplasty</title>
          <description>Hazard ratio of perforation or therapeutic penetrating keratoplasty (TPK) comparing voriconazole to placebo</description>
          <population>Comparison of rate of perforation or TPK between the treatment groups (topical voriconazole with oral voriconazole vs. topical voriconazole with oral placebo)</population>
          <units>New perforations or TPK/person-days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0095562"/>
                    <measurement group_id="O2" value="0.011204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size was determined based on the primary end point: perforation or the need for TPK within 3 months. Simulation-based analyses estimated that a sample sizeof 240 study participants (120 per arm) would provide 80% power to detect a 15% difference in the 3-month perforation or need for TPK rate between topical antifungal plus oral voriconazole vs topical antifungal alone,with a 2-tailed α value of .05 and approximately 15%loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional hazards regression to estimate the hazard of perforation or need for TPK.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Spectacle-corrected logMAR Visual Acuity</title>
        <description>Best spectacle-corrected logMAR visual acuity at 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
        <time_frame>3 months after enrollment</time_frame>
        <population>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and study site</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>Oral Voriconazole plus topical antifungal agents</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Oral Placebo plus topical antifungal agents</description>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-corrected logMAR Visual Acuity</title>
          <description>Best spectacle-corrected logMAR visual acuity at 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
          <population>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and study site</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7852594" spread=".1083858"/>
                    <measurement group_id="O2" value=".787141" spread=".1646131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Spectacle-corrected logMAR Visual Acuity at 3-weeks</title>
        <description>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
        <time_frame>3 weeks after enrollment</time_frame>
        <population>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and study site.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>Oral Voriconazole plus topical antifungal agents</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Oral Placebo plus topical antifungal agents</description>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-corrected logMAR Visual Acuity at 3-weeks</title>
          <description>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear</description>
          <population>Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and study site.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8745454" spread=".1080198"/>
                    <measurement group_id="O2" value=".744252" spread=".0964871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Infiltrate/Scar - 3 Months</title>
        <description>Size of infiltrate/scar at 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
        <time_frame>3 months after enrollment</time_frame>
        <population>Mean infiltrate scar size at three months correcting for baseline scar size and site</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>Oral voriconazole treated participants</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Oral Placebo plus topical antifungal agents</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Infiltrate/Scar - 3 Months</title>
          <description>Size of infiltrate/scar at 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
          <population>Mean infiltrate scar size at three months correcting for baseline scar size and site</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9319315" spread=".06508"/>
                    <measurement group_id="O2" value=".697005" spread=".0927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Infiltrate/Scar</title>
        <description>Size of infiltrate/scar at 3 weeks after enrollment, using enrollment infiltrate scar/size as a covariate</description>
        <time_frame>3 weeks after enrollment</time_frame>
        <population>Mean infiltrate scar size at three weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>Oral voriconazole treated participants</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Oral Placebo plus topical antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Infiltrate/Scar</title>
          <description>Size of infiltrate/scar at 3 weeks after enrollment, using enrollment infiltrate scar/size as a covariate</description>
          <population>Mean infiltrate scar size at three weeks.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".2192398" spread=".1663"/>
                    <measurement group_id="O2" value=".7973467" spread=".073885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hazard Ratio for Re-epithelialization</title>
        <description>Hazard Ratio of re-epithelialization comparing the treatment groups</description>
        <time_frame>Up to 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>oral voriconazole plus topical antifungal</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo plus topical antifungal</description>
          </group>
        </group_list>
        <measure>
          <title>Hazard Ratio for Re-epithelialization</title>
          <description>Hazard Ratio of re-epithelialization comparing the treatment groups</description>
          <units>Number re-epthelialized/person-days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0141123"/>
                    <measurement group_id="O2" value=".0130862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.49</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Cure at 7 Days</title>
        <description>Fungal Culture negative at 7 days post treatment</description>
        <time_frame>7 days</time_frame>
        <population>Fungal Culture negative at 7 days post treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Oral Voriconazole</title>
            <description>Voriconazole: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Cure at 7 Days</title>
          <description>Fungal Culture negative at 7 days post treatment</description>
          <population>Fungal Culture negative at 7 days post treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>Comparing the number of serious and non-serious adverse events by treatment arm.</description>
        <time_frame>3-months from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Voriconazole</title>
            <description>Voriconazole: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Comparing the number of serious and non-serious adverse events by treatment arm.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistically significant after Holms-Šidák correction for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Inhibitory Concentration of Isolates</title>
        <description>Comparing Minimum inhibitory concentration of isolates by treatment arm</description>
        <time_frame>3 months after enrollment</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over the entire course of the trial. (June, 2010-December 2015)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.</description>
        </group>
        <group group_id="E2">
          <title>Oral Voriconazole</title>
          <description>Voriconazole: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing &lt;40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction or stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Evisceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST or ALT elevated to five times the upper limit of normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer not healing after 6 weeks of therapy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Increase in hypopyon (increase&gt;2mm)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Local allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Other systemic event thought to be related to study drug</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatologic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST or ALT elevated to twice upper limit of normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Visual disturbances</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Ray</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-514-3227</phone>
      <email>kathryn.ray@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

